Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
Antimicrob Agents Chemother
http://www.ncbi.nlm.nih.gov/pubmed/28559269
© 2026 by the President and Fellows of Harvard College